Valuation: Center Laboratories, Inc.

Market Cap 2.37TCr 73Cr 65Cr 60Cr 54Cr 101.79Cr 6.87TCr 103.35Cr 719.43Cr 283.4Cr 3.6TCr 272.22Cr 266.39Cr 11TCr P/E 2024
-28.2x
P/E 2025 3.64x
Enterprise Value 2.77TCr 85Cr 76Cr 70Cr 64Cr 119.18Cr 8.04TCr 121.01Cr 842.37Cr 331.82Cr 4.21TCr 318.73Cr 311.9Cr 13TCr EV / Sales 2024
22.3x
EV / Sales 2025 23.1x
Free-Float
72.61%
Yield 2024
1.71%
Yield 2025 4.2%
11/08 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
21/07 GenEditBio Limited announced that it has received TWD 550 million in funding from Center Laboratories, Inc. CI
13/05 Center Laboratories says Jan-Mar net profit at T$1.97 bln RE
13/05 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
14/04 Center Laboratories, Inc. announces Annual dividend, payable on September 11, 2026 CI
31/03 WuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders. CI
03/03 Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
14/01 WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion. CI
11/11 Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
13/25/13 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/25/09 Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025. CI
09/25/09 Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million. CI
11/25/11 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 week-3.55%
Current month-4.32%
1 month-2.76%
3 months-17.50%
6 months-20.63%
Current year-24.54%
1 week 29.85
Extreme 29.85
31.2
1 month 29.85
Extreme 29.85
31.6
Current year 29.35
Extreme 29.35
48.96
1 year 29.35
Extreme 29.35
48.96
3 years 27.74
Extreme 27.739294
54.03
5 years 27.74
Extreme 27.739294
56
10 years 19.99
Extreme 19.990785
61.16
Manager TitleAgeSince
Chief Executive Officer - 03/08/1998
Director of Finance/CFO - 08/12/2022
Director of Finance/CFO - 01/08/2000
Director TitleAgeSince
Chairman - 30/11/2022
Director/Board Member 61 14/06/2010
Director/Board Member - 14/06/2010
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.55%-9.66%-26.95% 73Cr
+2.75%+4.79%+61.44%+127.46% 1,13300Cr
+4.20%+6.39%+39.66%+77.99% 62TCr
-0.14%+0.54%+24.60%+96.87% 50TCr
+0.03%+3.27%+39.79%+65.06% 38TCr
-1.03%+2.28%+69.50%+43.68% 37TCr
+1.58%+2.37%+22.91%+52.52% 29TCr
+2.90%+2.22%+3.51%+28.51% 26TCr
+2.24%+3.48%+51.74%+64.48% 24TCr
+2.07%-0.25%+29.24%+102.39% 19TCr
Average +1.42%+2.54%+33.27%+63.20% 39.89TCr
Weighted average by Cap. +1.84%+3.73%+43.33%+85.23%

Financials

2024 2025
Net sales 161.79Cr 4.96Cr 4.43Cr 4.09Cr 3.71Cr 6.96Cr 469.91Cr 7.07Cr 49Cr 19Cr 246.19Cr 19Cr 18Cr 779.92Cr 151.62Cr 4.65Cr 4.15Cr 3.83Cr 3.48Cr 6.53Cr 440.38Cr 6.63Cr 46Cr 18Cr 230.72Cr 17Cr 17Cr 730.9Cr
Net income -110.37Cr -3.38Cr -3.02Cr -2.79Cr -2.53Cr -4.75Cr -320.56Cr -4.82Cr -34Cr -13Cr -167.95Cr -13Cr -12Cr -532.05Cr 932.28Cr 29Cr 26Cr 24Cr 21Cr 40Cr 2.71TCr 41Cr 283.58Cr 111.71Cr 1.42TCr 107.3Cr 105Cr 4.49TCr
Net Debt 447.98Cr 14Cr 12Cr 11Cr 10Cr 19Cr 1.3TCr 20Cr 136.27Cr 54Cr 681.7Cr 52Cr 50Cr 2.16TCr 404.14Cr 12Cr 11Cr 10Cr 9.27Cr 17Cr 1.17TCr 18Cr 122.93Cr 48Cr 614.97Cr 47Cr 46Cr 1.95TCr
Projected Income Statement - Annual - Center Laboratories, Inc.
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
22/26/22 NT$29.90 0.00% 7,98,762
21/26/21 NT$29.90 0.00% 5,90,553
20/26/20 NT$29.90 -0.50% 5,86,110
19/26/19 NT$30.05 -3.06% 14,06,660
16/26/16 NT$31.00 +0.16% 7,59,987
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. 4123 Stock